Wells Fargo Initiates Coverage On Verona Pharma with Overweight Rating, Announces Price Target of $50
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo has initiated coverage on Verona Pharma with an Overweight rating and set a price target of $50.
October 03, 2024 | 2:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo has initiated coverage on Verona Pharma with an Overweight rating and a price target of $50, indicating a positive outlook for the stock.
The initiation of coverage with an Overweight rating and a $50 price target by Wells Fargo suggests a positive sentiment towards Verona Pharma's stock, likely leading to increased investor interest and potential upward price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100